Shikari® (Q-DEN) Denosumab ELISA

Enzyme immunoassay for the quantitative determination of denosumab (Prolia®) in serum and plasma. 

This kit has been especially developed for the quantitative determination of denosumabin serum and plasma samples between the Cmin and Cmax range of concentrations.

Denosumab Drug Bank Accession Number is DB06643.

Denosumab is a RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. In many bone loss conditions, RANKL overwhelms the body's natural defense against bone destruction. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary. 

All SHIKARI® ELISA kits are suitable for biosimilar work. 

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com